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Apoptosis is essential to normal growth and development. Discrepancies in the timing, 
location, and progression of apoptosis produce a number of conditions. More specifically, 
abnormalities in the expression of c-Myc, a transcription factor that regulates cell growth and 
development, have been correlated with cell proliferation. Expression of Bcl-2, a 
mitochondrial protein, antagonizes the apoptotic function of c-Myc. A multifaceted approach 
is introduced that seeks to inhibit c-Myc, Bcl-2, and c-FLIP. Synthetic nucleic acids, called 
aptamers, have been selected against a number of pathogenic proteins and are a promising 
means of inhibiting these protein targets. Aptamers bind with high specificity and high 
affinity to their protein targets and are powerful tools in diagnostics and therapeutics. 
Aptamers against c-Myc, Bcl-2, and c-FLIP are expected to provide a new avenue for the 
activation of apoptosis in diseased cells which refuse to die. The results from multiple rounds 











Apoptosis, a form of programmed cell death, is essential to normal growth and 
development. It is implicated in a number of processes, including embryonic development and 
disease progression. It is in essence an organized method of cellular suicide. Due to the 
importance in timing, location, and progression of apoptosis, nature has developed a tight 
system of control over the various pathways that have been identified1. Abnormalities within 
this complex framework, e.g. inducing cell death when inhibition should occur or vice versa, can 
lead to various diseases and conditions. The objective is to research a new avenue for the 
activation of apoptosis in diseased cells which refuse to die. 
At the cellular level, apoptosis commences when the cell receives extracellular signals 
on one or more of its death receptors1. Known pathways include Fas-mediated, TNF-related, 
and TRAIL-induced1, 2. The progression of apoptosis, which is far more complicated than simple 
ligand-binding, is an intricate system of checks and balances (Fig. 1) further complicated by 
numerous activations and inhibitions carried out by relevant macromolecules that often lead to 
conflicting signals. c-Myc is one such macromolecule3. It is capable of causing both cell cycle 
progression and apoptosis3,4, and it is hindered in its apoptotic activity by Bcl-2 and c-FLIP5,6. 
While these proteins are certainly not the only macromolecules involved in the regulation of 
apoptosis, they are nonetheless significant and require further analysis.  
c-Myc is a transcription factor encoded by the c-Myc gene, which is composed of three 
exons, the first of which is noncoding3,7. Two promoters, P1 and P2, effect 90-95% of all c-Myc 
transcription, and lead to the formation of 2.2 and 2.4 kb mRNAs and subsequently 64-67 kDa 
c-Myc proteins3. The protein is found in the nucleus and exhibits both nonspecific and site-
specific DNA binding at E-box domains (-CACGTG-)8,9. The RNA binding affinity of c-Myc protein 
is not well characterized, though it has been shown that RNA is not co-purified with c-Myc10. 































      
           Figure 1: The role of c-Myc, Bcl-2, and c-FLIP in cell cycle progression and apoptosis, 























    A surprising attribute of c-Myc is its instability—half-life of approximately thirty 
minutes3. So what accounts for their presence and activity in living systems? Stability is attained 
by dimerization with Max, a similar protein encoded by a different gene10. Myc-Max 
heterodimers confer tight binding to DNA, allowing for more adequate transcriptional 
regulation of genes involved in cell signaling3,11,12. 
    The role of c-Myc in growth and development is not clear, and it has been shown that c-
Myc can both induce and inhibit cell death (Fig. 2). Research in antisense oligonucleotide 
technology has revealed that a decrease in c-myc mRNA levels, and a subsequent decrease in c-
Myc protein levels, results in growth inhibition and/or apoptosis13,14. The ambiguity in c-Myc 
function necessitates that any proposed method of inducing apoptosis in a Myc-related 
pathway, must take into consideration the ability of c-Myc to cause cell cycle progression. In 
addition, the proposed method should seek to understand the regulation of c-Myc-induced 
apoptosis. These considerations are the precise reason for the multifaceted approach sought 
here. Inhibition of one pathway is not enough to induce apoptosis—effective inducement can 
only be achieved by executing inhibition of all c-Myc-induced pathways. 
______________________________________________________________________________ 
 







Figure 2: (a) Death arises because of conflict of signals. Under normal conditions, c-
Myc promotes cell growth, but in the absence of serum, apoptosis results. (b) “Dual 
Signal” hypothesis.  Under normal conditions, c-Myc induces both cell proliferation 
and apoptosis. Adapted from Evan et al. 
 
    The pathway in which c-Myc acts as an activator of apoptosis is the main thrust of this 
research. There is an important protein called Bcl-2 in this pathway, which inhibits c-Myc-
activated Bax/Bid (Fig. 3), a heterodimer found in the mitochondrial outer membrane that 
increases permeability of the membrane to cytochrome c and Smac/DIABLO15,16,17. These serve 
as signals for the activation of caspase cascades, which unleash proteases, called caspases, 










    Bcl-2 was the first of a family of pro-apoptotic and anti-apoptotic proteins to be 
characterized and is overexpressed in a number of cancers such as B cell lymphomas16. Studies 
on CED-9, a homologue of Bcl-2 found in C. elegans, demonstrate the upstream negative 
regulation characteristic of Bcl-2 function18. Inhibition of Bcl-2 is linked to tumor regression by 
apoptosis19. 
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Figure 3: (A) Bax/Bid is upstream of Bcl-2. (B) Bax/Bid is downstream of Bcl-2. (C) Bax/Bid 
and Bcl-2 act independently to regulate apoptosis. Adapted from Chao and Korsmeyer. 
 
    In a different, but related, pathway, tumor-necrosis-factor-related-apoptosis-inducing-
ligand (TRAIL) causes cell death by binding to a death receptor, TRAIL-R, which recruits a 
molecule called Fas-associated via death domain (FADD) and causes activation of a caspase 
cascade1,2,6. TRAIL shows promise as a cancer therapeutic, but with one caveat20. The inhibitory 
protein of interest here, cellular FLICE-inhibitory protein (c-FLIP), antagonizes the 
transformation of procaspase-8 into its active form and, like Bcl-2, prevents cell death20,21. 
    c-FLIP was first identified as a human cellular homolog of v-FLIP, a herpes virus FLIP 
capable of inhibiting death-receptor-mediated apoptosis22. Likewise, expression of c-FLIP is 
implicated in tumor progression23. The c-FLIP gene, located on chromosome 2, resembles both 
its homolog v-FLIP and procaspase 8, with death effector domains (DED) and caspase-like 
domains (Fig. 4). FLIPs inhibit apoptosis by competing for DED binding sites on FADD, thereby 





     Figure 4: Structural similarities between caspase 8 and FLIP. Adapted from Krueger et al. 
 
A number of studies has shown that expression of both Bcl-2 and c-FLIP result in the 
inhibition of Myc-mediated apoptosis24,25,26,27,28,29.  Present research, especially cancer 
research, seeks to describe the imbalances in gene expression and/or protein formation that 
are characteristic of cells which refuse to die. Various technologies, such as siRNA, antisense 
oligonucleotides30, antibodies31, and aptamers, have been employed in the characterization of 
apoptosis pathways.  
    Characteristics that make aptamers powerful tools in diagnostics and therapeutics are 
their high specificity and high binding affinity33,34. Identification of nucleic acid aptamers against 
a number of pathogenic proteins has revealed a generalized inhibitory function. Aptamers 
against c-Myc, Bcl-2, and c-FLIP have not yet been identified. This research will employ the 
selection of RNA aptamers in understanding the roles of c-Myc, Bcl-2, and c-FLIP in cell death, 
as well as in the analyzing the interactions among these proteins. The ultimate goal is to 
discover a novel method for the inducement of cell death, with key applications for the 










Pools—The selections were performed using the N70.01 and N35 random sequence 
pools, with 1013 complexity (provided by Bradley Hall and Shawn Piasecki, respectively). The 
synthesis of the pools is similar in technique to that described in Hesselberth et al. (2001).  
Sequence—N70.01 
5' – ATGCGTAGGCGTGTAACTTG - N70.01 - CACATTACAAGCTCGCCAGT - 3' 
Forward primer—N70.01 
5' – TTCTAATACGACTCACTATAGGATGCGTAGGCGTGAACTTG - 3' 
Reverse primer—N70.01 
3' - GTGTAATGTTCGAGCGGTCA - 5'. 
Sequence—N35 
5’ - CACAGCGGGACAGTTTAGC - N35 - GGTAGGTGGGTGCGTCTAAA - 3’ 
Forward primer—N35 
5’ – GATAATACGACTCACTATAGGGCACAGCGGGACAGTTTAGC – 3’ 
Reverse primer—N35 
3’- CCATCCACCCACGCAGATTT -5’ 
In Vitro Selection—Equimolar amounts (200 pmol) of RNA and protein were incubated 
at room temperature for 30 min following heat denaturation of the RNA (65 °C for 5 min, room 
temperature for 10 min). Binding and nonbinding species were separated by pushing the 
reaction through a nitrocellulose filter, with pores large enough to pass free nucleic acids but 
too small to pass those bound to protein. Binding species that were caught on the filter were 
thrice eluted with 50 mM EDTA, 5 M urea, and 0.3 M sodium acetate to give a final volume of 
400 μL. Beginning with the third round, filter binders were excluded by passing the denatured 
RNA over a nitrocellulose filter prior to the addition of protein. Ethanol precipitation was 
performed to isolate the selected RNA, and reverse transcription was performed with 
SuperScript II reverse transcriptase (Life Technologies, Inc.) and the appropriate reverse primer. 
The cDNA products were amplified by polymerase chain reaction after the addition of the 
forward primer and Taq DNA polymerase (Invitrogen). The dsDNA PCR amplified products were 
transcribed with the Ampliscribe T7 Transcription Kit (Epicentre). The reactions were incubated 
at 37°C for 6 hrs, denatured with 2X Denaturing dye, and run down a PAGE gel. The RNA was 
eluted a final time, and then quantified. 
The dsDNA selection follows the same procedure, with the exception that reverse 
transcription and transcription were not performed. 
Additional Negative Selections—c-FLIP is commercially available as a GST-tagged 
protein. GST, or Glutathione S Transferase, is often used in the purification of proteins. Its 
presence will require the usage of negative selections to exclude RNA species that bind to GST 
and not to c-FLIP. This will be achieved by first incubating the RNA pool with GST, collecting the 
flow-through containing RNA species that do not bind to GST, and finally incubating with GST-c-
FLIP. Negative selection against GST will begin with round three. 
Binding Assays—Following six and ten rounds of selection, the percent binding of the 
RNA pool was ascertained. The dsDNA from rounds one, three, four, five, six, eight, and ten 
were transcribed using a radioactive nucleotide, [a-32P]ATP (3000 Ci/mmol, NEN Life Science 
Products). Elution and quantification proceeded as usual. The binding reactions were passed 
simultaneously over two filters, nitrocellulose and nylon. The percent binding is calculated by 
the relative amounts of radiation present on each filter. All binding is calculated above 
background binding, which is related to the amount of radiation present for the negative 
control containing nucleic acids and no protein. 
 
 
RESULTS AND DISCUSSION 
  As previously described, there is some uncertainty in the RNA binding abilities of the
transcription factor c-Myc. Two
RNA, but a gel of the PCR products showed no 
pool RNA did not bind to the protein. Though these results strongly suggest that c
RNA binding characteristics, it is entir
weak.  
For the first round of selection, 1.3 μg of 
molecules in 13.5 μL) was incubated with an equimolecular amount of protein (approximately 
1012 molecules in 2 μL). The PCR cycle cou
cycle 8; thus, large scale PCR was carried out to six cycles.
ng/μL; 1:10 dilution gave 556.2 ng/μL), and a recalculation gave 1.3 μg in 2.34 μL to be
the next round. 
 
    The second round of selection was not as successful. Difficulties arose in reverse 
transcription of RNA. The resuspension
was successful, though the reverse transcription separated into two layers, the bottom milky 
white and the top clear, after a week at 











 rounds of selection were performed using the N70
definable bands, which indicated
ely possible that binding does occur but is transient and 
N70.01 pool RNA (approximately 10
rse gel (included below) showed overamplification at 
 The DNA was quantified (4793.1 
  
Round 1 c-Myc 
 of the precipitated cDNA prior to reverse transcription 
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-Myc lacks 
13 
 used in 
the sample became contaminated. Alternatively, it may be that the cDNA was not properly 
resuspended (e.g. overdried nucleic acids fail to dissolve completely).  
    The cycle course from one round for Bcl-2 is shown below. The concentrations from RNA 
quantification following large scale amplification to cycle 7 and cycle 13, respectively for rounds 
1 and 2, are found in Table 1.  
 






 Selections against c-Myc and Bcl-2 were reevaluated following two rounds of selection 
with N70.01 pool RNA. A shorter random region was used instead, and ten rounds of selection 
were performed with N35 pool RNA. The results were promising, as expected. Table 2 shows 
PCR cycle courses and RNA quantifications from the first eight rounds.  
  
Table 1 Round 1 (μM) Round 2 (μM) 














































Table 2 c-Myc 





















































































































































































































































































































































































































































































































































































































The results from ten rounds of selection were assayed for percent binding of target 
protein to N35 pool. Significant results are demonstrated in the assay of round 9 binding for 
Bcl-2, which indicates good binding above background as well as good binding relative to an 
identical assay without protein. Cloning and sequencing of round 9 of selections against Bcl-2 
may provide promising results for the identification of specific aptamers against Bcl-2; these 



































Protein c-Myc (a.a. 1-262) Bcl-2 minus C terminus GST-c-FLIP (a.a. 1-481) 
Supplier Santa Cruz 
Biotechnology, Inc. 
R&D Systems Abnova Corporation 
Catalog Number sc-4084 827-BC-050 H00008837-P01 
Molecular Weight 65 kDa 27 kDa 78.8 kDa 
Weight 50 μg 50 μg 25 μg 
Volume 1 mL 335.6 μL N/A 
Concentration 0.77 μM 5.52 μM N/A 
Buffer Supplied as 50 μg 
purified protein in 
PBS containing 5 
mM DTT and 50% 
glycerol. 
Supplied frozen as a 
0.2 μm filtered 
solution in 10 mM 
HEPES (pH 8.0) and 
0.1 M KCl and 20% 
glycerol.  
 
Supplied in 50 mM Tris-
Hcl, 10 mM reduced 
Glutathione, pH=8.0 in 
the elution buffer. 
Price $150 $350 $390 
Number of Rounds 
Possible 
3.85 9.25 1.59 
Price per Round $39.00 $37.79 $245.86 
Quantity 3 1 0 
Total Price $450 $350 $0 
     
c-FLIP was not be purchased because of the high price per round (a typical round should 
cost approximately $50). Selections against this protein were not carried out because it could 






    By virtue of pool nucleic acid folding complexity, it is expected that aptamers will be 
successfully selected against each protein target. However, the selection of aptamers that 
exhibit a significant percentage of binding to each protein target is dependent on the extent of 
each protein’s ability to bind RNA. In the case of low binding affinity, more rounds of selection 
were carried out, and percentage binding was assessed again.  
    Once sufficient binding percentages were achieved, DNA from round 9 of selection 
against Bcl-2 was cloned—this process is ongoing. It is expected that potential aptamers will 
induce cell death, though their activities will have to be evaluated in a number of ways. For 
example, the aptamers can be placed in cancer cells to assess their effect on cell death. Both 
direct and indirect means of inhibition can be employed. The former method can be carried out 
by direct use of inhibitory aptamers and the latter by conjugation of toxins, proteases, and 
other apoptosis-inducing molecules to aptamers. Additionally, these aptamers may be used as 
biomarkers for various conditions. 
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